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Abstract 
Acute promyelocytic leukemia (APL) is 
characterized by arrest of leukocyte differentiation at 
the promyelocyte stage. In classic APL, the central 
leukemia-initiating event is the chromosome 
translocation t(15;17)(q22;q21) resulting in the 
fusion of the retinoic acid receptor-alpha (RARA) 
gene on 17q21.1 with the promyelocytic leukemia 
(PML) gene at 15q24.1. In rare cases, RARA is fused 
with genes other than PML that gives rise to APL 
variants such as in der(2)t(2;17)(q32;q21) with the 
underlying NABP1/RARA fusion gene. 
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Clinics and pathology 
Disease 
Acute promyelocytic leukemia (FAB type M3) 
Epidemiology 
Only 1 case to date, a 59-years old male patient (Won 
et al., 2013). 
Clinics 
The patient presented with anemia, 
thrombocytopenia, and high white blood cell count 
with 61% blasts and abnormal promyelocytes. BM 
aspirate revealed 69.2% microgranular abnormal 
promyelocytes. Immunophenotype analysis was 
positive for CD13, CD33, CD45, CD65, and MPO 
with negative CD34, HLA-DR, and B-cell and T-cell 
markers (data from Won et al., 2013). 
Treatment 
Therapy with all-trans retinoic acid (ATRA) was 
initiated but it was discontinued after 2 days due to 
the negative PML/RARA molecular result. 
Induction therapy with idarubicin and cytarabine 
was started but ATRA was restarted 7 days later 
when RARA rearrangement was identified by 
fluorescence in situ hybridization (FISH). The 
patient achieved complete remission on day 28, and 
underwent allogenic stem-cell transplantation after 2 
cycles of consolidation chemotherapy. He remains 
alive and in complete remission one year after 
transplantation. 
Prognosis 
The leukemic cells from the patient showed 
neutrophilic differentiation in the in vitro all-trans 
retinoic acid assay and the patient achieved complete 
remission with ATRA therapy, therefore 
NABP1/RARA fusion appear to be an ATRA-
sensitive variant in APL. 
Cytogenetics 
Cytogenetics morphological 
Presented as der(2)t(2;17)(q32;q21). 
Cytogenetics molecular 
RARA rearrangement by FISH. 
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Additional anomalies 
t(11;19)(q13;p13.1) in a subclone. 
Genes involved and 
proteins 
NABP1 (nucleic acid binding protein 
1) 
Location 
2q32.3 
Protein 
The nucleic acid binding protein 1 (NABP1, 
previously known as OBFC2A; 
oligonucleotide/oligosaccharide-binding fold 
containing 2A) gene encodes human single-stranded 
DNA binding protein 2; essential for a variety of 
DNA metabolic processes including genomic 
stability, replication, recombination; plays a role in 
DNA damage response and in detection and repair of 
damage (Richard et al., 2008). 
RARA (Retinoic acid receptor, alpha) 
Location 
17q21.2 
Protein 
Retinoic acid receptor-alpha is a nuclear retinoic 
acid receptor, implicated in regulation of 
development, differentiation, apoptosis, 
granulopoeisis and transcription; the encoded 
protein function as heterodimers with retinoid X 
receptors;  regulates expression of target genes in a 
ligand-dependent manner by binding to retinoic acid 
response elements and, when bound by ligands, 
recruit a protein complex to activate transcription. 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
5' NABP1 - 3' RARA 
Transcript 
RARA portion of the transcript started in exon 3 and 
was fused in-frame to exon 5 of OBFC2A; 
breakpoint in RARA gene in the same breakpoint as 
in previously described fusions of RARA. 
Fusion protein 
 
Schematic diagram of NABP1, RARA and NABP1/RARA fusion protein. DBD, DNA binding domain; LBD, 
ligand?binding domain. 
Description 
NABP1-RARA predicted to encode a 551-amino 
acid protein; NABP1 5'-region encoding the DNA-
binding domain (DBD) is fused to the 3'-region of 
RARA including the DBD and ligand-binding 
domain (Figure 1. adopted from Won et al., 2013). 
Oncogenesis 
Patient with NABP1-RARA fusion shows a similar 
breakpoint within the RARA gene sharing a 
common portion as in other APL cases; therefore the 
chimeric protein is expected to behave as an altered 
retinoic acid receptor. The retention of the N-
terminal oligonucleotide/oligosaccharide-binding 
fold in NABP1 protein that binds to single-stranded 
DNA substrate may provide the possibility of 
dimerization and produce oncogenic signaling 
leading to accumulation of undifferentiated 
promyelocytes. 
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